Biocom: Bringing Your Concerns to to You LifeLines · 2020. 2. 20. · CUBIST 45,000 SF / Sublease...

DNA in Action: The Next Chapter in San Diego’s Sequencing Saga

VOLUME 24, ISSUE 2 Sum me r 2015

9

14

17LifeLinesFor the Southern California Life Science Community

Biocom: Bringing Your Concerns to Policy Makers And Policy Makers to You

What Does Biocom Membership Mean for Me?

Volunteering to Grow and Diversify the STEM Pipeline

(858) 452-6500 BRENT JACOBS CA LICENSE NO. 791657

GREG BISCONTI CA LICENSE NO. 1167920

TED JACOBS CA LICENSE NO. 1855220

ONE TEAM. ONE FOCUS. www.sdlifesciences.com

TENANT REP FOR THE LIFE SCIENCES INDUSTRY

DEXCOM, INC.218,000 SF / Tenant Representation

ALTHEADX70,000 SF / Tenant Representation

VERENIUM / BASF60,000 SF / Tenant Representation

TORREYANAApril 3, 2013

San Diego, CA

Exterior View @ South FacadeARCTURUS THERAPEUTICS10,000 SF / Tenant Representation

BIOCOM10,900 SF / Tenant Representation

MIRATI THERAPEUTICS18,000 SF / Tenant Representation

CUBIST45,000 SF / Sublease Disposition

GENOMATICA70,000 SF / Tenant Representation

GENZYME / SANOFI64,000 SF / Sale Disposition

WELCOME TO L I FEL INESWelcome to the second edition of LifeLines for 2015, part of our continuing

celebration of Biocom’s 20 years of success. We are proud to represent the longest-

established life science association in California and the leading advocacy voice for the

Southern California life science community.

Frankly, there is no other life science cluster in the world quite like ours, with its

innovative research and technology, collaborative culture, exceptional opportunities for

professional achievement and superior recreational and cultural environment. When

Albert Einstein arrived for his first visit, 85 years ago, he remarked, “I feel that you

are justified in looking into the future with true assurance, because you have a mode

of living in which we find harmoniously combined the joy of life and the joy of work.” I

think you’ll agree that the same holds true today.

Our members work together to make Biocom a harmonious association that helps

lead this great life science innovation ecosystem and project our industry’s voice

throughout Southern California, Sacramento and Washington, DC.

We are especially pleased by Biocom’s global membership growth, with many

members from life science clusters in Japan and southern France who want to partner

with our Southern California members. Our board and senior management team are

completing a bold new strategic plan, which will help Biocom accelerate life science

success and guide our community into an even more prominent global role.

In keeping with the leadership theme, our cover story focuses on the next chapter

in our region’s sequencing saga. A mere decade after the first commercial roll-out of a

next generation sequencing instrument, Southern California has emerged as a hotbed

for genomics. We are putting petabytes of genetic data to work to more efficiently

develop new diagnostics and therapeutics.

In advocacy, the most pressing issue is at home. We discuss how Biocom is working

with elected officials to address our members’ concerns about California’s ongoing,

severe drought. In addition, you will read about our recent Biocom town hall meetings

and roundtables with NIH director Dr. Francis Collins, FDA/CDRH director Dr. Jeffrey

Shuren, House Democratic Whip Steny Hoyer and Reps. Scott Peters and Xavier

Becerra.

The remainder of this issue is filled with interesting stories about what Biocom

membership means for individual employees, our improved Office Depot Purchasing

Group contract and how our Biocom Institute helps companies give back to the

community. We review our successful Festival of Science & Engineering while

previewing the first-ever AdvaMed Annual Convention in San Diego, which Biocom will

cohost this October.

The Biocom team and our board continue to work hard to ensure that we remain

the leading life science association in California, with a focus on accelerating our

membership’s success. Please enjoy this issue of Lifelines, and I hope you’ll stay in

touch with us at Biocom’s beautiful new life science community headquarters on Torrey

Pines Mesa.

2 Cover Story: DNA in Action: The Next Chapter in San Diego’s Sequencing Saga

8 Biocom Briefly: FDA will miss departing chief -- San Diego, too

9 Public Policy : Bringing Your Concerns to Policy Makers And Policy Makers to You

10 Public Policy : The Consequence of Drought

12 Guest: San Diego Welcomes AdvaMed 2015

14 Membership Update: What Does Biocom Membership Mean for Me?

17 Biocom Institute: Volunteering to Grow and Diversify the STEM Pipeline

18 Science Festival: San Diego Festival of Science & Engineering – An Epic Success

20 Members in Action: BIO Over the years, Biocom Golf Tournament

25 Purchasing Group: Biocom Purchasing Group: Reaching New Heights

26 Premium Member Spotlights: Alexandria, COI Pharmaceuticals, Jones Day, KPMG, Biocom

30 Biocom Board and Committees

31 Biocom Membership

EDITOR : Jennifer LandressCOPY EDITOR : Josh BaxtDESIGN & LAYOUT: Arlene Arreola

V O L U M E 2 4 , I S S U E 2

WELCOMEI N T H I S I S S U E

WWW.BIOCOM.ORG

By Joe Panetta, President and CEO, Biocom

Biocom, a member driven or-ganization, is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your com-pany with saving money, advo-cacy, increased visibility, net-working opportunities, capital development and workforce development.

Biocom LifeLines Spring 2015 1

By 2025, people all over the world will have their full genome sequenced within hours of birth. This information will serve as a fundamental piece of their electronic medical record and a baseline against all future sequencings—procedures that will be as ordinary as a cholesterol check.

That’s the prediction of Gavin Stone, who leads corporate development and marketing at fast-growing Edico Genome.

“In 10 years’ time, our reality will be extremely precise, extremely personalized medicine,” Stone says. “Everyone will have their genome and microbiome sequenced on a regular basis and get results back in a matter of minutes, probably while they’re still at the doctor’s office.”

If doctors spot any DNA sequence variations that might indicate disease, they can respond swiftly with the right treatment.

Edico Genome, which is settling into its new Torrey Pines offices after recently graduating from San Diego’s EvoNexus technology incubator, has created a faster and more affordable method for interpreting the vast quantity of data produced by today’s next-

generation sequencing machines. The company recently entered into a partnership with Intel Corp. to speed up the process even more, potentially enabling real-time genome analysis.

After all, Stone notes, what’s the use of detailed genomic data if researchers or clinicians can’t make sense of it quickly?

Edico Genome is one of more than a dozen biotech companies throughout Southern California that are finding new ways to translate DNA data into actionable healthcare information. It’s a mission that extends all the way to the White House, where President Obama spoke out earlier this year against one-size-fits-all medicine and announced funding for genetic-based cancer research as part of a precision medicine initiative.

San Diego—with its unique ecosystem of biotech innovators, DNA sequencing giants and computing expertise—is already pushing the boundaries of what’s possible with personalized healthcare. And it’s doing so on many fronts, from Illumina’s development of the first FDA-approved next-gen sequencing system for clinical labs, to a wide variety of molecular diagnostic and bioinformatics

DNA in Action: The Next Chapter in San Diego’s Sequencing Saga A mere decade after the first commercial rollout of a next-generation sequencing instrument, San Diego has emerged as a hotbed for companies taking the next step—turning reams of genomic data into treatments and cures.

COVER S TORYBy Kelly Quigley

2 Biocom LifeLines Summer 2015

COVER S TORY

companies that are helping physicians detect and treat disease earlier than ever before.

Grappling with Gigabases Given the flurry of action in clinical genomics, it’s hard to believe

that just one decade ago the first next-gen sequencing machine was about to hit the market.

The Genome Sequencer 20 System arrived first—a product from 454 Life Sciences, now a division of Roche. Months later came Solexa’s game-changing Genome Analyzer, which promoted its ability to sequence 1 gigabase of data in a single run. At the time, such a claim was nearly unbelievable.

San Diego-based Illumina acquired Solexa in 2007 and went on to lead the global sequencing market—with data output more than doubling each year, exceeding Moore’s law. Today, Illumina’s most powerful system, geared towards population-scale sequencing, produces up to 1,800 gigabases of data in a run.

That’s a whole lot of data to deal with. But too much data is rarely a bad thing, says Adam Simpson, president and chief operating officer of San Diego-based Cypher Genomics, which provides human genome sequencing interpretation software and a biomarker discovery service.

“It’s really a thrilling problem to have,” Simpson says. “You have 3.2 billion base pairs of information in your body. Now the question becomes: How do you utilize this information so it becomes useful for clinical diagnostic laboratories and pharmaceutical companies?”

Cypher Genomics recently joined forces with San Diego-based molecular diagnostics company Sequenom to develop noninvasive prenatal tests that pinpoint chromosomal abnormalities usually not detectable until after birth. The company is also working with drug companies to identify disease biomarkers hidden in sequencing data. The goal is to foster new diagnostics and targeted therapies on a rapid timeline, bringing precision medicine to life.

“Even two years ago, the conversation was still about the price and analytical validity of sequencing,” Simpson says. “Today, you can safely assume that you’ll have an affordable and completely accurate genomic sequence. The conversation is now about clinical application.”

Beyond the $1,000 GenomeThe fact that a clinically focused conversation can even exist

today is rooted in economics, says Kim Kamdar, partner with

healthcare venture capital firm Domain Associates, also based in San Diego.

“Just over a decade ago, it cost $3 billion to sequence one human genome,” she says, referring to the price tag of the Human Genome Project, completed in 2003. “The second one was $100 million. At those prices, you can’t really understand the basis of disease. You can maybe look at one or two genomes, but not a thousand genomes of people who have a particular type of cancer and compare those to a thousand genomes of healthy people.”

Today, as the $1,000 genome becomes a reality (Illumina declared success on this front in 2014 with the launch of its HiSeqX Ten system), genomic data can more easily move from the discovery bench to the patient’s bedside.

And the economics factor doesn’t just stop at the cost of sequencing a genome. One of the main market drivers for personalized medicine is the need to lower overall medical costs. Quality of patient outcomes is at the forefront, too, but it all boils down to delivering care as efficiently—and affordably—as possible. “It’s really getting at a fundamental issue

that we have in healthcare,” Kamdar says. Genomic-based medicine offers a clear benefit in its ability to

detect disease earlier and direct people to the best therapies right off the bat.

“The economic benefits of genomics are clear,” adds Simpson of Cypher Genomics.

However, Simpson notes, before the full economic benefits can be realized, U.S. health insurance companies must do a better job of embracing genomics as a standard element of patient care.

Big Data from Small SamplesBiotech players in San Diego are enabling precision medicine

in many different ways. While companies like Edico Genome and Cypher Genomics are focused on how to alleviate the bottleneck of genomic data, others are working to find more effective and less intrusive methods for gathering actionable DNA from patients.

For example, rather than relying solely on DNA from the initial tissue biopsy to direct cancer treatment, companies are using their technology to track disease progression and drug response by capturing microscopic particles of tumor DNA from blood or urine.

“Once the sequencer has revealed that a patient has a mutation, you know you want to use a certain drug. But now our interest turns to tracking how the mutation changes. We want to know when that cancer comes back before an imaging study shows metastasis

“TODAY, YOU C AN SAFELY ASSUME THAT YOU’LL HAVE AN AFFORDABLE AND COMPLETELY ACCURATE GENOMIC SEQUENCE . THE CONVERSAT ION IS NOW ABOUT CL IN IC AL APPL IC AT ION.” - -ADAM S IMPSON, PRES IDENT & COO, CYPHER GENOMICS

Continued Pg 5


Experience How Everything We Do Has A Single Focus - Your Success[ ]

Focusing on private companies preparing to go public or be acquired, we provide aaest and tax services to a wide variety of

public companies, early-stage and growing private companies.

We are one of San Diego’s largest Life Sciences and Technology Praccces.

COVER S TORY

everywhere,” says Antonius Schuh, CEO of Trovagene, which offers noninvasive tests to detect and monitor various cancer mutations.

Trovagene’s technology extracts tumor DNA from urine samples and analyzes it using Illumina’s next-gen sequencing equipment. Results reveal whether the tumor is shrinking or if resistant mutations have emerged. With this information, doctors can modify the course of treatment at great speed. And because urine samples can be obtained so easily, patients’ progress can be tracked completely noninvasively on even a daily basis.

“I want to know in real-time whether this new drug is resulting in accelerated cancer-cell death,” Schuh says. “I can do this from urine in a very powerful manner, observing a spike in genetic material that results from dying cancer cells.”

In April, Dr. Hatim Husain, of the UCSD Moores Cancer Center, presented data from a clinical study showing that Trovagene’s urine-based Precision Cancer Monitoring platform detected the emergence of a rare resistance mutation in metastatic lung cancer patients with greater sensitivity than a tissue biopsy—and months before it could have been detected with imaging equipment.

Trovagene’s tests focus on mutations that are known to play a role in cancer and for which targeted therapies are available. As more biomarkers are discovered and drugs developed, Schuh notes, the potential for testing expands.

A few miles north of Trovagene, Epic Sciences is likewise developing highly sensitive diagnostics tests that detect and track disease noninvasively.

Epic has more than 30 different cancer-focused assays that work on patient blood samples. The company’s “no cell left behind,” technology captures whole cancer cells circulating in blood—cells that were nearly impossible to detect before. The company then genetically profiles the cells to provide insights into disease status.

In addition to helping guide treatment, Epic’s analyses also inform the development of new pharmaceuticals and companion diagnostics. Epic CEO Murali Prahalad was formerly a vice president at Carlsbad-based sequencing behemoth Life Technologies, which is now a brand of Thermo Fisher Scientific. And before that, he worked for Sequenom.

Such talent crossover occurs throughout the San Diego sequencing scene and is what makes the area such a stronghold for innovation in the genomics space, Kamdar says.

“If you just look at Illumina and Life, the two main players in the sequencing space, and you look at the talent they’ve spawned, you see there’s a large group of people in San Diego who have been

quietly and confidently amassing the type of information needed to bring genomics to the clinic,” she says.

Factor in San Diego’s dominance in biological research, mobile health, computing (notably, Qualcomm) and the bold presence of

people like genomic industry trailblazer J. Craig Venter, and it’s easy to understand why San Diego is leading the way.

Speaking of Venter, one of his most recent business ventures—Human Longevity Inc. (HLI) in San Diego—is a genomics and cell therapy-based diagnostic and drug company that’s operating squarely in the precision medicine space.

The company is building the largest human genotype and phenotype database in the world, with the ambitious goal of extending the high-performance lifespan

and changing the face of aging. “We envisioned a new era in medicine when we founded HLI,

in which millions of lives will be improved through genomics and comprehensive phenotype data,” Venter said in a statement his company released earlier this year when he participated in the White House precision medicine event.

The company’s comprehensive database is already in place, with thousands of complete human genomes, microbiomes and phenotypic information together with accompanying clinical records. The data is enabling the pharmaceutical industry, academics, physicians and patients to advance understanding of disease and wellness and to apply the knowledge to personalized care.

Coming Soon: Faster, Cheaper, BetterGiven that five years ago hardly anyone foresaw the speed at

which genomes would be sequenced today—or the plethora of potential clinical applications underway—is it even possible to predict how the clinical genomics scene will look in five or 10 years? Probably not with anything close to 100 percent accuracy, but there are some things most industry leaders agree upon.

First, sequencing will continue to get faster and less expensive, and it will be possible on increasingly compact instruments.

Meaningful analysis of genomic data for translation to clinical application also will accelerate. Information will deepen as more biomarkers are discovered—and biomarker discovery will surge as more people get sequenced.

“To figure out cancer, we need to sequence hundreds of thousands of cancer genomes,” Illumina CEO Jay Flatley has said.

Noninvasive diagnostics, such as those from Epic Sciences and Trovagene, will benefit from advances in biomarker discovery and

GIVEN THAT F IVE YEARS AGO HARDLY ANYONE FORESAW THE SPEED A T WHICH GENOMES WOULD BE SEQUENCED TODAY—OR THE PLETHORA OF POTENT IAL CL IN IC AL APPL IC AT IONS UNDERW AY—IS I T EVEN POSS IBLE TO PREDICT HOW THE CL IN IC AL GENOMICS SCENE WILL LOOK IN F IVE OR 10 YEARS?

Continued Pg 6


will be able to provide increasingly real-time disease profiling for even more conditions. And pharma stands to gain too, with more therapies developed to address newly discovered mutations.

In addition, the industry will find new ways to elicit health-relevant knowledge from DNA, as San Diego’s BioNano Genomics already is doing with its whole-genome mapping and structural variation technology.

“You will reach a point in the next 10 years where the sheer ability to detect and measure will become a commodity aspect,” Schuh predicts. “In sequencing, the value will continue to shift from the sheer collection of the data to the solutions that integrate clinical practice. It boils down to how we bring this to the patient.”

Edico Genome’s Stone guesses that the next wave of innovation, after widespread clinical adoption of genomic medicine, will be a surge in consumer applications—bringing sequencing technologies into a home environment.

On the government and policy front, he predicts that within 10 years (but hopefully sooner) payers and healthcare systems will have worked out the data privacy and reimbursement issues that are currently in debate.

The industry also will have come together to agree on sequencing standards and protocols—something that’s just starting to happen

now. Illumina joined with four major cancer centers earlier this year to form the Actionable Genome Consortium, which provides guideless to helps oncologists diagnose, classify and treat cancer. And in May, the U.S. National Institute of Standards and Technology made available “reference” DNA that gives labs a unified way to check if their sequencing machines and software are properly analyzing genomes.

In another decade, there’s no question that precision medicine will be flourishing. While surely there will be room for improvement, healthcare will be significantly more precise than it is today and genomics will play a much larger role.

And in San Diego, which gave birth to today’s thriving sequencing scene, the biotech community will be hard at work on the next big thing.

Kelly Quigley is content director at Canale Communications and a former biotech journalist. At Canale, she specializes in thought leadership strategy and content development for life science

companies.

Roche DiagnosticsScience that spans the spectrum of healthcareUse the same innovative molecular technologies in your drug discovery that are trusted in clinical diagnostics.

For life science research only. Not for use in diagnostic procedures.

MagNA Pure 96 Instrument LightCycler® 480 Instrument

For more information, visit http://lifescience.roche.com or contact your Roche representative. LIGHTCYCLER, MAGNAPURE, and COBAS are trademarks of Roche. © 2015 Roche 408-61332-0515

cobas® 4800 System

COVER S TORY

Last month, Dr. Margaret Hamburg announced her impending resignation at the end of this month as commissioner of the U.S. Food and Drug Administration after leading the agency for nearly six years.

She will step down leaving a legacy of a significantly improved track record for novel drug approvals while at the same time having successfully increased public confidence in drug safety.

When Hamburg began her tenure at FDA, she was faced with low morale among staff as a result of continued scandals and congressional scrutiny over such issues as contaminated food and drugs being imported from China and undisclosed side effects of several widely used medicines.

She also came in at a time when funding for life science innovation was threatened by the growing economic crisis.

Dr. Hamburg began her relationship with Biocom soon after she arrived at the FDA, her interest focused upon a survey that we have conducted periodically over the last 16 years in partnership with PricewaterhouseCoopers (PWC) titled “Improving America’s Health V: A Study of the Working Relationship Between the Life Sciences Industry and FDA.”

In 2010, shortly after Dr. Hamburg took over at FDA, Biocom and PWC issued our fifth edition of the survey, which identified numerous challenges facing the FDA under the new health care law, including the mandate to establish a review pathway for biosimilar drugs and a profound lag in the FDA’s ability to keep pace with the rapidly evolving scientific and technical advances in drug and device technology. To her credit, the new commissioner brought Biocom and PWC to the FDA to further explore with her team how the FDA could effectively respond to our findings; we believe the current iteration of the survey, released in February, is an indication of the commissioner’s success over the last five years with more than 75 percent of industry executives indicating that the FDA has improved the quality of its communication and more than 70 percent indicating that feedback and guidance on new regulations had also improved substantially.

While the San Diego life science community gives the commissioner solid marks for the progress that has been made during her tenure, the FDA faces profound new challenges in the future, including meeting congressional priorities to approve more so-called “breakthrough therapeutics” under the 21st Century Cures Act, a new Precision Medicine Initiative announced by the president in his State of the Union address, as well as increased consumer and payer focus on cost-effectiveness and improved

outcomes. All of these issues will have a profound impact on the success of the San Diego life science community in the future in which the primary focus is on these types of products.

The new FDA commissioner will have to face pressure to better meet the new demands for approval of innovative products with greater flexibility and more of a need to demonstrate value.

Our recent survey concluded relatively few consumers believe that the FDA incorporates their views in the review process; it will be essential that the new commissioner address these concerns as it will also impact our industry’s ability to demonstrate value over currently available therapies.

With increased consumer access to medical information including personal health care records and individual genetic sequencing data, consumers are assuming responsibility for information that will without a doubt place greater pressure on the FDA to coordinate and collaborate more with patients. Additionally, the future success of the FDA will be dependent upon the ability of a new commissioner to meet expanding responsibilities to address groundbreaking legislation while taking leadership of regulation within an ever-expanding global marketplace for health care products.

San Diego’s life science community is at the epicenter of the development of breakthrough therapies and personalized medicine technologies, with a rapidly growing consumer-focused wireless health sector resulting from the convergence of long-established telecommunications and medical device industries. Our future, and the future of the patients for whom these products are being developed, will lie in large part with the appointment of effective new leadership to not only follow on the path that Commissioner Hamburg has created, but to provide bold new leadership as well.

This Opinion piece originally ran in the U-T San Diego on March 20, 2015.

BIOCOMBRIEFLY

FDA will miss departing chief -- San Diego, too

By Joe Panetta, President & CEO, Biocom


We are halfway through 2015, and although it’s already been quite a year, the road ahead is filled with challenges and opportunities. The question we are getting most from our members, elected officials and the media is: How will California’s ongoing drought affect the life science industry? To be honest, no one knows.

Biocom is in regular contact with the stakeholders most affected by this crisis, including agencies who supply Southern California’s water. They have repeatedly stated that California can achieve the Governor’s 25 percent water reduction mandate by curtailing ornamental and outdoor water use, including lawns, landscaping and water features. But every Californian must help. If we cannot achieve the 25 percent reduction by limiting these cosmetic uses, then it becomes more likely we will have mandatory shutoffs, which will affect California’s economic drivers, including the life sciences. We will keep our members apprised of the latest developments, including local regulations to decrease water use.

In March, Biocom was honored to co-host (with the California Healthcare Institute) a town hall meeting at UCSD with NIH director Francis Collins, who also paid a visit to Biocom member company Organovo. Dr. Collins was excited by the groundbreaking innovation at Southern California companies, and how that is accelerating discoveries and solutions. In April, FDA CDRH director Jeff Shuren visited our members via Skype for a lively and candid session at our quarterly member breakfast. We were also proud to host Congressmen Scott Peters, Steny Hoyer and Xavier Becerra for legislative roundtables. Bringing important decision-makers to our members is an important part of what we do.

Biocom’s Washington DC office continues to engage the government on a number of fronts. The two biggest priorities have been educating members of Congress on the potential effects of different patent reform bills and providing input as Congress continues to develop its 21st Century Cures legislation.

Some of these patent proposals could have devastating effects on the life science industry, particularly for small companies who may find it harder to protect their intellectual property. On the other hand, 21st Century Cures could be an opportunity to modify and streamline systems so new therapies, cures and devices can get to patients faster. You can read the comments Biocom has offered on these issues in the federal policy section of the Biocom website.

At the state level, exciting legislation introduced by San Diego’s

own Speaker of the Assembly Toni Atkins has been gaining ground. This legislation would allow monetization of accrued R&D tax credits for small companies, something Biocom has long sought in the state policy arena. Now that Speaker Atkins has put her considerable influence behind getting these provisions into law, we hope she will make the difference.

Earlier this year, Biocom, PhRMA, BIO, CHI several patient groups and many individual companies combined to help stall an onerous state bill (AB 563), which would have required itemized disclosure of all costs associated with bringing any individual drug (costing $10,000 per therapeutic course) to market. The bill will be considered again in January, 2016, if not sooner through a different vehicle. This legislation is part of a nationwide effort by health plans to blame the rising cost of healthcare squarely at the feet of the drug industry, even though data indicates prescription drug spending as a percentage of the health care dollar has not risen in decades. This organized and well-funded campaign of distortion is being met head-on by the industry, but continues to gain traction.

The Biocom Public Policy department continues to be your voice to decision-makers. We encourage you to watch the BCQ for the most current news in the policy arena and how it will affect your company.

Jimmy Jackson is the Senior Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

PUBL IC POL ICY

Biocom: Bringing Your Concerns to Policy Makers And Policy Makers to You

By Jimmy Jackson, Senior Vice President of Public Policy, Biocom


It’s 1991 and California is in the midst of a significant drought. The San Diego City Council proposes shutting off water to all manufacturers for two to three hours per day to conserve precious water – not realizing the effect shutoffs will have on the local life science industry. A number of CEOs meet to discuss the issue and decide water shutoffs would cripple their companies. Several approach the San Diego City Council, giving them an overview of the industry and explaining why water can’t be shut off to their businesses.

As a result of these efforts, the city initiates the Guaranteed Water for Industry Program, which secures water access for companies, up to drought level two, provided they implement water saving measures. March Miracle rains come and shutoffs are no longer necessary. However, industry and service providers decide they have further interests to pursue together and Biocom is born.

Flash forward to 2015. California is again experiencing an historic drought: a fourth dry year with no relief in sight. April marked the first time in 75 years there was no snow at 6,800 feet in the Sierra Nevada Mountains. Overall, the snowpack was 5 percent of its historical average, 28.3 inches.

On May 5, the State Water Resources Control Board approved the first mandatory water conservation rules in state history. Effective June 1, all cities and water districts must achieve mandatory reductions between 8 and 36 percent (based on per capita water use) of their 2013 baseline. Governor Brown has said he will support legislation authorizing fines of up to $10,000 per day for cities and districts that don’t meet these targets.

These rules stem from the Governor’s April 1 executive order, directing the state water board to reduce potable water usage by 25 percent statewide. The final target for the City of San Diego is 16 percent. In addition, the City of Oceanside must reduce water consumption by 20 percent, the Carlsbad Municipal Water District by 28 percent and the City of Poway by 32 percent. Local water agencies have enacted various restrictions to achieve these goals, including cutting back outdoor irrigation, limiting water service in restaurants and hotels and using recycled water where possible. Regulators say saving urban water is the cheapest and most effective way to ensure communities have enough and avert more drastic cuts.

In December, San Diego received 3.5 inches of rain, which led to a 29% reduction in water use. Because of this, we are confident that the 25% statewide reduction target can be achieved solely

through limiting outdoor irrigation, which accounts for 44% of water use in California. However, if targets cannot be reached through outdoor restriction alone, we anticipate regulators will consider shut off periods. Given that we believe legislators and water regulators understand the importance of the life science industry to the state, we hope they will consider all other avenues before implementing shut off periods.

Biocom was founded 20 years ago to educate local officials about water access. Our members depend on a reliable, constant source of water for everyday business. Interrupting these supplies could mean millions of dollars lost in delicate research and production. Biotech and pharmaceutical companies have long been leaders in adopting water saving technologies, such as water recapture and recirculation systems for water intensive machinery.

Biocom has supported a number of practical ways to diversify the region’s water supply, such as potable reuse and desalination, and has worked closely with local and state water officials to communicate the industry’s importance to the regional economy.

With luck, a developing El Niño will ease the crisis. But regardless, Biocom will be working closely with all stakeholders to help maintain a steady water supply for Southern California’s life science industry.

Melanie Nally is the Associate Director of Local Government and Regulatory Affairs and also heads our facilities and EHS committees.

PUBL ICPOL ICY

The Consequences of Drought

By Melanie Nally, Associate Director of Local Government & Regulatroy Affairs, Biocom


Build on Advantage

TRANSFORMING REAL ESTATE INTO REAL

ADVANTAGEFor every client, advantage is delivering

the broadest, deepest reach and resources

any real estate company offers.

Transforming property into prosperity,

square feet into strong portfolios,

scale into global strength. All in service

of exceptional outcomes that build

real business advantage. Let us put our

actionable perspectives, global reach

and powerful connections to work

for your business.

cbre.com/sandiego-occupier @cbresandiego

The medical technology industry is constantly innovating, developing new products and procedures that enhance and save lives around the world. Each year, the Advanced Medical Technology Association hosts the largest gathering of medtech companies and investors at AdvaMed 2015: The MedTech Conference. Here, industry leaders meet for strategic business development, high-level networking and world-class education.

Now in its ninth year, AdvaMed 2015 will be held for the first time in San Diego, October 5-7. The 2015 conference will offer enhanced business development programming—providing better opportunities for early and emerging growth companies, as well as investors and business development executives.

Early-Stage and Emerging Growth OpportunitiesAdvaMed 2015 seeks to foster growth among start-up companies

developing new, life-saving and life-enhancing devices, diagnostics and digital health technologies. The conference will provide an array of programming for these innovators, including:

• Emerging & Early Growth Company Issues Panels – Learn from industry leaders, policymakers and peers about the latest trends, challenges and opportunities facing the industry.

• Entrepreneurship Boot Camp – Learn how to develop an actionable strategic plan.

• Innovation Showcase – Startups pitch technologies to investors and consolidators.

• MedTech Partnering – A one-to-one meeting solution designed to maximize networking opportunities for medtech companies and other industry stakeholders

Business Development & InvestorsAdvaMed 2015 offers exclusive programming and a unique

environment for senior business development executives and investors from across the industry to connect and explore opportunities for strategic partnerships and investment.

• Innovation Showcase & MedTech Innovator – Discover the latest medical technologies and innovations.

• Business Development & Finance Panel Sessions – Gain insights into the key issues driving medtech investment and deals.

• MedTech Investor Forum and Business Development Roundtable (invitation only) – Prominent health care investors and top medtech business development executives will come together to share ideas and discuss trends in the marketplace.

• Strategic Investor Speed Dating (invitation only) – Active health care investors and leading corporate business development teams will be paired for brief one-on-one meetings with promising early-stage medtech companies in the Innovation Showcase.

• Investor – Business Development Reception (invitation-only) – MedTech investors, strategic business development executives and small company innovators will gather for networking immediately preceding the conference’s opening reception.

By the NumbersIn 2014, The MedTech Conference welcomed more than 2,300

attendees from 29 countries. Twenty-three of the top 25 medical device companies bring representatives from across their organizations. From c-suite to management, the conference attracts leaders of all levels. Last year, 24 percent of attendees were at the c-suite or president level; 21 percent were vice presidents; 19 percent were executive directors and directors; six percent were partners; and the remaining 30 percent included managing partners, managers, general counsels and others.

GUEST

San Diego Welcomes AdvaMed 2015

By Ray Briscuso, Managing Partner, AdvaMed 2015: The MedTech Conference

Business DevelopmentAbbott LaboratoriesB. Braun Medical, Inc.Baxter International, Inc.Bayer HealthCare, LLCBDC. R. Bard, Inc.Cardinal HealthCareFusion CorporationCovidienDanaher CorporationEdwards Lifesciences CorporationFlextronics MedicalGE HealthcareHill-RomHollister IncorporatedHospiraIntegra Life SciencesIntuitive SurgicalJohnson & JohnsonMedtronic, Inc.Owens & MinorPhilips HealthcareQuidelSorin S.p.A.St. Jude Medical Stryker CorporationTerumo CorporationThermo Fisher ScientificZOLL MedicalFinance and Investment

Abbott Ventures Ampersand Capital PartnersArboretum VenturesAscension Ventures Athena Investment GroupBaird CapitalBaxter VenturesDeloitte Corporate Finance LLCInternational Finance CorporationJVC Investment PartnersLightstone VenturesLinden Capital PartnersLionBird VenturesMass Medical AngelsMoelis & CompanyMorgan StanleyOrbiMed AdvisorsPiper JaffrayPritzker GroupPTV Healthcare CapitalRCT VenturesRiver Cities Capital FundsRoundTable Healthcare PartnersThomas, McNerney & PartnersVersant VenturesWater Street Healthcare PartnersWilliam Blair

Nearly 400 business development, investment and finance executives attended AdvaMed 2014, including representatives from these companies:


Other Programming:• 30+ Educational Panels• 4 Plenary Sessions • 30+ Industry CEO Speakers • 4 Networking Receptions• 120+ Exhibitors • 40 Innovation Showcase Companies

We look forward to collaborating with Biocom to make this conference a success. Register today and we will see you in October.

Ray Briscuso is Managing Partner for Advamed 2015: The MedTech Conference

GUEST

Make Your Mark in BiotechnologY

The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/psmlifelines

Professional Science Master’s

HURRY!Fall 2014 Start

APPLY TODAY

Here’s a common question: My company is a Biocom member; does that mean I am, too?

I’m pleased to say yes, that’s exactly what it means. We have worked hard for 20 years to expand our membership benefits, encouraging personal and professional development while saving you money. Here’s a taste of your Biocom benefits.

Never Stop LearningWhether you’re looking to move from

the lab bench to a leadership position, improve your public speaking and presentation skills or, if you’re new to the industry, want to better understand the life science space, we offer professional courses at discounted rates.

Get Involved If you’re interested in sharing your

life science industry knowledge, discussing current trends or growing your professional network, join a committee. If you don’t have enough time, come to some of our 75 educational and networking events. We believe that bringing people together to learn and socialize is a great way to inspire each other, while keeping our community vibrant and strong.

Give BackGet involved with the Biocom Institute and give back to a veteran

or future innovator. The Biocom Institute’s veteran’s initiative is focused on assisting veterans with mentoring and career assistance and providing introductions to life science companies. The San Diego Festival of Science & Engineering promotes all things STEM, getting students of all ages excited about science, technology, engineering and math. Interested in becoming a big sister or bother? We’ve partnered with Millennium Health and Big Brothers Big Sisters of San Diego County to pair Biocom members with 11 to 13 year-old girls and boys.

Making Your Life Better and Easier We’re trying to remove barriers so you can focus on the things

you love, both inside and outside of work. We’re constantly

looking for different ways to improve the health and happiness of our members. Biocom Concierge is an all-inclusive network of our member services, from travel to photography to 401ks. The Biocom employee perk program is designed for employees

at Biocom member companies. We’ve partnered with many of your favorite San Diego businesses to bring you personal and exclusive discounts and benefits.

We Care About You AND Your Family Your family matters to you, so

they’re important to us, too. With discounts to SeaWorld, Knott’s Berry Farm, Hyatt Hotels and National Car Rental, to name a few, we offer something for everyone.

Stay Healthy

You’re in the business of saving lives and you need to be healthy to succeed. Biocom members receive discounts for classes at barre3, personal training at Fitness and Motion, gym memberships at the Lawrence Family Jewish Community Center and more.

We want our benefits to work for you, so we assess all our offerings regularly and adapt them to the needs of our changing industry.

Keep an eye out for our new employee resource guide, which details all these perks and more, and check back often to discover additional benefits and discounts.

If you have any questions, or ideas for fun new benefits we should be offering, please let me know. I can be reached at 858.455.0300 x123 or [email protected].

Sonali Vitacchi is the Sales Support Coordinator for Biocom.

MEMBERSHIP

What Does Biocom Membership Mean for Me?

By Sonali Vittachi, Sales Support Coordinator, Biocom

We’ve got you!Biocom Member Employee Resource Guide

you are Biocom. Get involved. Save money. network.

Your company is a Biocom member and guess what? You are too! We have lots of perks for your company but did you know that we have something for You Too?

Looking for some discounted SeaWorld tickets? Want to take a professional development class? How about a chance to network with other profesSionals?

Are you social? We are too! Check out our pages/wall/feed for the scoop on upcoming events, member news, and more.

We can deliver directly to your emailSign up for our bi-monthly electronic newsletter and our Upcoming Events newsletter at www.biocom.org.

/Biocom @BiocomCA /Biocom @BiocomCA

Who wouldn’t want to save money? We’ve partnered with many of your favorite SoCal businesses to bring personal and exclusive discounts and benefits to our members. With discounts to SeaWorld, Knott’s Berry Farm, Hyatt, barre3 UTC and much more! We are always adding new perks, check back often to discover additional benefits and savings.

We know that you want to! If you’re interested in sharing your knowledge of the industry with our life science professionals, discussing current trends or growing your network, then join a committee today.

CommitteeS Employee Perks Program

BCQ Biocom’s life science newsletter

BioCommunique

CONCIERGELooking for a particular service? With an all-inclusive network of our members’ services, ranging from travel to photography to professional development, Biocom Concierge is your one-stop-shop. www.biocomconcierge.org

CLASSESThirsty for more knowledge? Want to improve your corporate value? We have courses to invigorate the pep in your step and bring your skills to the next level. Whether you need help with public speaking, presenting, leadership or understanding science lingo, we have what you need.

You deserve

EmployeesRULE!

some PERKS!

ww

w.b

ioco

m.o

rg


OPERATIONAL EXCELLENCE. STREAMLINED SOLUTIONS.For over 160 years, VWR has been growing strong because of our unique approach to collaborating and encouraging innovation with our customers. Over time they

have been challenged with finding the answers that help improve lives. Our mission is to enable this by eliminating the process complexities and identifying product and

service solutions that help labs and production facilities work better, faster, and smarter. Through our global reach and knowledgeable associates, we proudly excel in delivering

solutions that improve productivity, accelerate discovery, and encourage innovation.

DRIVING SUPPLY CHAIN INNOVATION Supply Chain is more important now than ever.

Among VWR's strengths is knowledge and expertise in logistics - ensuring the right products are reaching our customers on time, every time.

Our customer focused approach offers total solutions, from discovery in research and education to production, and delivering operational excellence on a global scale to:

Together, VWR and Biocom combine their core strengths to offer total solutions that advance scientific innovation in the life sciences, providing you with substantial cost savings and service solutions

to accelerate science from discovery to production. Extend your purchasing power by taking advantage of the power of the VWR - Biocom partnership, and realize a total solution platform, so you can

focus on what's truly important: Science.

• Reduce total cost of acquisition - with streamlined procurement to fill orders quickly and efficiently.• Drive supply chain security - to minimize your risk.• Ensure product quality - with every order.

Biocom_85x11.indd 1 5/18/2015 2:07:15 PM

Our industry offers many ways to give back to the community that make good business sense as well. Many Biocom member companies are already involved with patient advocacy groups. Another logical initiative is to grow and diversify the STEM pipeline. Whether you or your colleagues have a passion for explaining science to kids or helping veterans in their transition from military service, our charitable organization, the Biocom Institute, has volunteer opportunities for everyone. Check out our website at biocominstitute.org and contact us today to take advantage of these opportunities.

Help VeteransAround 13 percent of San Diego’s population is military. Whether

you are a veteran or interested in giving back to a veteran, we have a number of opportunities. Volunteers can develop or participate in programs to assist veterans through our Veteran Initiatives Committee or engage in one-on-one mentoring through our Veteran Career Mentoring Program.

There are many ways to contribute and some that don’t require a lot of time. Even if you cannot contribute today, if you are currently working in the life science industry and are a veteran or are interested in helping veterans, we want to know who you are. We will keep you abreast of our veteran programs and events so you can participate when the time is right.

Teacher Fellows Program Are you a scientist, engineer or other STEM professional? We

offer ways to reach hundreds of students without ever leaving your lab or office.

Because the best way to reach these students is through their chemistry, math, science and physics teachers, the Biocom Institute launched our Fellows Program. Fellows attend a major international industry conference, an industry networking mixer and best practices seminars, as well as have an opportunity to shadow you at work – running tests, designing experiments, managing projects and performing other useful tasks. Fellows are eager to take these experiences back to the classroom and share them with their students.

San Diego Festival of Science & Engineering The Festival is a great way to get out into the community and

showcase your company’s science, technology or engineering expertise. As an exhibitor, you have the amazing opportunity to watch the sparkle in each kid’s eyes as they stop by your booth to participate in your activity. Exhibitor or not, we always need volunteers throughout the week, especially at Expo Day, where we see more than 24,000 kids and families at Petco Park.

If you would rather be in the schools, we are also looking for professionals to visit K-12 classrooms. You don’t have to be a scientist or engineer, just passionate about your company’s mission and able to communicate to kids.

Beyond School Walls STEM ProgramAre you interested in becoming a big sister or big brother but

can’t find the time? We have partnered with Millennium Health and Big Brothers Big Sisters of San Diego County to pair Biocom member employees with 11 to 13 year old girls and boys from Innovation Middle School.

During the program, which runs through the 2015/2016 school year, you meet with your little brother/sister for 90 minutes every other Wednesday, from 1:45 to 3:15 pm at our Biocom offices. The first 30 minutes will be an organized STEM program. During the remaining time, you can take advantage of the amenities around our offices, such as yoga and fitness classes, Torrey Pines State Park, basketball, board games on the patio and more to spend quality time with your little brother or sister.

Help ignite the spark of enthusiasm for all of the great work being done in our local life science industry by sharing your talents and knowledge.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR Initiative.

BIOCOMINST I TUTE By Liisa Bozinovic,

Executive Director, Biocom Institute

Volunteering to Grow and Diversify the STEM Pipeline


Nearly 90,000 STEM enthusiasts went all-in for science during the seventh annual San Diego Festival of Science & Engineering last March. For one week, San Diego County businesses, universities and professionals hosted events to showcase the business of science in Southern California and inspire K-12 students to consider STEM careers.

Without the generosity of philanthropic businesses, we would not be able to continue our mission to provide opportunities for youth from all backgrounds to participate in hands-on activities, meet real scientists and engineers, and learn how recent discoveries and research affect our daily lives.

Thank you 2015 San Diego Festival of Science & Engineering sponsors and partners – YOU help us spark the imaginations of future innovators and, possibly, future employees.

2015 Honor Roll• Presenting Sponsor: Illumina • Gold Sponsors: ABC10 and Aztec 15, The City of San Diego,

Diversity in STEAM Magazine, Microsoft, Qualcomm, San Diego Padres and ViaSat

• Silver Sponsors: Biocom Purchasing Group, CBS Radio, Cox Communications, Hologic, Inc., Reuben H. Fleet Science Center, San Diego County Office of Education, Time Warner Cable and VWR

• Copper Sponsors: Ackerman Foundation, County of San Diego, Cubic Corporation, Cymer, Ferring Pharmaceuticals, Scatena Daniels Communications, Think Blue San Diego, Thermo Fisher Scientific, UTC Aerospace Systems and Vertex

• Krypton Sponsors: Bank of America, Mission Federal Credit Union, Northrop Grumman, Pfizer, Inc. and Sequenom

• Titanium Sponsors: AT&T, D&K Engineering, EMD Millipore, General Atomics, Kaiser Permanente, International Bridge Technologies, LEGOLAND California, Point Loma Nazarene University, San Diego National Defense Industry Association, STEM Job and Raytheon

• We Love STEM Sponsors: American Elements, Canale Communications, Promo Shop, San Diego Financial Literacy Center, Thermo Fisher Scientific, UTC Aerospace Systems and Vertex

• Partners: CSU San Marcos, San Diego State University, STEAM Connect and UC San Diego

Think, Drink, Science – Brewing a SparkWhen children come to our events, their faces light up. We want

to fuel this same spark for adults, and believe our new program –Think, Drink, Science – is a great way to start. Craft beer is a burgeoning industry in San Diego, and since our goal is to show how science and engineering are right in our backyard, this event is a great way to expose the intricate science behind beer – something many of us enjoy daily. If we can get parents hooked on STEM education, it will pave the way for students to embrace it as well.

We are honored to have The Homebrewer host our inaugural event on August 15.

“Beer has always found itself at the happy crossroads between science, technology, culture, and economics,” said George Thornton, owner of The Homebrewer. “Or perhaps those things have always been happy to have beer along for the ride. Countless findings about our world have been in part because of our curiosity about fermentation, alcohol and beer. Events like this are simply a continuation of this long line of fascination. You can call it evolution. We’re thrilled to be a part of this conversation and to work with such a great team.”

San Diego is a hotbed for scientific innovation, offering a uniquely collaborative spirit, high concentration of world-class research institutions and a strong foundation to create and develop new companies. Our festival is a catalyst to transfer that knowledge and collaboration and show students and parents how science translates into careers and fuels our economy.

Save the date for the 2016 San Diego Festival of Science & Engineering, which kicks off with EXPO Day on March 5, 2016 with an amazing Festival Week to follow. To sponsor or exhibit, visit www.lovestemsd.org.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

SCIENCEFESTIVAL

San Diego Festival of Science & Engineering – An Epic Success

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

THINK DRINK SCIENCESaturday, August 15th

R S V P : W W W. L O V E S T E M S D . O R G


SCIENCEFESTIVAL

SAN DIEGO FESTIVAL OF SCIENCE & ENGINEERING EXPO DAY: From left to right: Congresswoman Susan Davis congratulates Molly of Solana Santa Fe Elementary School on being a recipient of the 2015 STEM Design award; The love of science is for all ages, as families engage together at EXPO Day 2015; A father-son team work together to build their molecular structure out of mini-marshmallows; Attendees at the Biocom Institute Booth talk about their STEM heroes; A spark is ignited as a future employee of Illumina has fun learning about DNA; Winners of the Bright Idea Society award, from High Tech High, teach students about Cyanotyping; An inside look at the mechanics behind D & K Engineering during Festival Week., Excitement enfolds as students have a “closer look”.


MEMBERS IN ACTION

BIO OVER THE YEARS: The BIO International Convention is the world’s largest, most influential biotech meeting that regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development. San Diego has played host to the BIO International Convention three times in 2001, 2008 and 2014 and we look forward to having the Convention return on June 19-22, 2017. Biocom’s participation in the Convention has been strong through the years as we showcase the Southern California life science region, despite where the convention is hosted.


MEMBERS IN ACTION

n Increasetheefficiencyoftargetedcapture—benefitfrom2.1millionoverlappingprobes.

n Discovermorevariantswhileoptimizingsequencingefficiency—multiplexupto12samplesinalaneandachievehighercaptureunifor-mity,minimizingyoursequencing.

n New!Overnighthybridization protocolincreasesyourspeedtodiscovery.

SeqCap EZ Choice Target Enrichment SystemSequence what matters Whole Genome Sequencing can be difficult. Your target enrichment choice is EZ... SeqCap EZ Choice.

For more information, visit www.nimblegen.com/seqcap or contact your Roche representative.

For life science research only. Not for use in diagnostic procedures. NIMBLEGEN and SEQCAP are trademarks of Roche. © 2015 Roche 408-60986-0515

MEMBERS IN ACTION

BIOCOM GOLF TOURNAMENT: The 4th Annual Biocom Golf Tournament benefiting the Biocom Institute and San Diego Festival of Science & Engineering was an even bigger success than last year thanks to the engagement and support of our sponsors and golfers. It was a great day and we raised over $25,000, all of which will go directly towards supporting transitioning military veterans and STEM outreach.

THANK YOU TO OUR SPONSORS:

AER TravelHyatt House

Office DepotEnterprise National

Charles RiverVeolia

Anthem Alexandria

Thermo Fisher ScientificVWR Catalyst


ProSciTM

© 2015 ProSci Incorporated. All rights reserved.

prosci-inc.com | [email protected] | (858) 513 2638

• >12,000 custom antibody projects completed since 1998• In-house labs & 150,000 ft2 of animal facilities on 27 acres• USDA licensed & NIH/OLAW assured facilities

Need Antibodies? Go to ProSci.

ProSci is an antibody focused company and a leading provider of custom antibody services and catalog antibodies worldwide.

Have You Considered the Single Domain Antibody Advantage?

Features & Benefits• Smallest functional antibody unit (~15 kDa)• High affinity and specificity• High solubility and stability• Cost effective large scale production• Research, diagnostic, and pharmaceutical applications

Order by July 31, 2015 to get 20% off!

Call or visit prosci-inc.com/single-domain-antibody

ProSci offers sdAb services from immunization to production

ConventionalAntibody

Camelid Heavy Chain Antibody

VHH or Single Domain Antibody

(sdAb)

We pride ourselves on the progress we’ve made in our RFP processes, securing best-in-class products and services essential to the success of the life science industry, but it’s been a real journey getting here.

Back in 2003, we were a young organization with limited resources. We leveraged the BIO association and their affiliate network to help us negotiate better terms and conditions on behalf of our members. We offered nominal value to RFP respondents through support and member engagement, and our collective contract spend was modest in our earlier stages.

Despite those challenges, we conducted an office supply bid, and Office Depot retained the Biocom Purchasing Group endorsement. Strong discounts were implemented, and most of our members saw significant savings and value in the contract. Since then, we have extended the contract three times, with each new term producing an increase in contract participation, discount structures and member-only benefits and services.

As of June 2014, our Office Depot contract had grown into a nationally-competitive program, attracting attention from even a few of our larger companies within our association.

Our Members Wanted More – and so Did We. Last summer’s office supply RFP held significant ramifications

for all parties involved. For Office Depot, it signified a potential validation of their longstanding endorsement against fervent competition and a chance to cement themselves as the clear leader in our industry. For their competition, it represented premier access to our member base and the opportunity to cause considerable shifts in market share. For our members, it symbolized the redistribution of power between buyer and seller in concessions on discounts, reporting tools and customer service programs.

For the Biocom Purchasing Group, it presented a first real test to see if our “all grown up” GPO could demand and secure a contract that would compete with big pharma and fortune 500 companies. This new bid would be based solely on the cachet of our contract participation, value proposition and negotiating prowess. We were looking for a contract that would change the game, and all the major competitors were invited. We solicited volunteers from companies of all sizes within our member base. Their goal was the same as ours; bring home a contract that would compete on the global stage.

Armed with committed spend, verified volume and projections, significant member investments and a robust support system, we

issued an RFP that required a level of attention usually seen from a large global customer or big pharma. We knew the responses we received would reflect how far we had come as a GPO.

Despite all of their posturing, our RFP participants knew a valuable opportunity when they saw one. After all, if we were asking for the moon and the stars, we knew we had to present them with a significant opportunity for this whole thing to work.

So did it? I’m happy to report that – after nine months of presentations, follow ups, deliberations and negotiations – we have ourselves a new office supply contract. Office Depot dug deep and came to the table with a globally competitive contract that was bigger, bolder, broader and better than ever before. This was a huge win for them and our members.

New GPO Heights. This contract win suggests we are well on our way to becoming

a world-class GPO. Together with several of our other more recent RFP recipients (UniFirst, Unisource Solutions, TransPerfect, PRNewswire, etc.), we can now offer unprecedented, globally-competitive contracts. This is great news for our members, as they continue to gain exclusive access to game-changing programs, substantial cost savings and unique Biocom-only terms, conditions and services. With projections of more than $125 million in savings for 2015, and RFPs for lab supplies and gasses on the immediate horizon, we will continue to reach new heights as a GPO and achieve operational excellence for our member companies.

If you are a current customer under the Office Depot/Biocom contract, you should already be seeing the improved prices, higher-level cost savings, reporting enhancements, increased sales support and contract customization. If you are not yet a customer and/or Biocom member, give us a call and come reach new heights with us!

Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

PURCHASING GROUP By Rick Fultz,

Managing Director, Biocom Purchasing Group

Biocom Purchasing Group: Reaching New Heights


Name: Jason MoorheadJob title: Assistant Vice President, Asset Services

Favorite movie: Amélie; and most recently The Imitation GameFavorite books: The Goal, Shop Class as SoulcraftFavorite quote: Gandhi: “If we could change ourselves, the tendencies in the world would also change. As a man changes his own nature, so does the attitude of the world change towards him. ... We need not wait to see what others do.”

Favorite TV show: I don’t have cable TV, so don’t see much, but recently enjoyed Outlander on NetflixFavorite restaurant or meal: Simon Pearce, VTFavorite city: ParisFavorite actor/actress: Keira KnightleyFavorite thing to do on the weekends: Use my Balboa Park Explorer Pass with my familyWhat CD can we find in your car: The Jam – All Mod ConsFavorite hobby: Restoring vintage oddities (primarily Vespa & Lambretta motor scooters)

Favorite website: Craig’s List (to search for vintage oddities to restore)Favorite spot in Southern California: Secret beach spot in La JollaFirst job: Lab Technician, The Salk InstituteFavorite part of your job: Learning about the life-changing work being performed in the laboratories of Alexandria’s client tenants.If you could have another career, what would it be: Category 1 bicycle mechanic working the Giro d’ItaliaWhy did you start working in your industry: I have always been intrigued by scientific discovery, and found a way to contribute to the advancement of life sciences by supporting the built environment where improvements to human health are made.

PREMIUM MEMBER SPOTLIGHTS

www.are.com

AbbVieAirgasAldevron*Alexandria Real Estate EquitiesAltheaArena PharmaceuticalsBayer HealthcareBiogen*Biomed Realty TrustBiospaceBP BiofuelsCalifornia Manufacturing Technology

ConsultingCanale CommunicationsCelgeneCity National BankCOI PharmaceuticalsConatus Pharmaceuticals

Cooley LLPDeloitteDLA PiperEli LillyErnst & YoungEvaluate Pharma*Ferring Research InstituteFisher ScientificFoley & LardnerGE Healthcare Life SciencesGenoptixHologicJ-LabsJones DayKPBSKPMG*Latham & WatkinsMallinckrodt Plc

MentusMerck Research Laboratories of San DiegoMintz, Levin, Cohn, Ferris, Glovsky and

PopeoNuVasiveOffice DepotPfizerPraxairPrometheus LaboratoriesPwCThermo Fisher ScientificUnisource SolutionsVWR InternationalWilson Sonsini Goodrich & Rosati

PREMIUM MEMBERS

* New Members from January 2015 to May 2015


No other tenant representation firm represents more life science companies in San Diego. Below is a select listing of engagements we have completed in the last year.

30,000 SF Expansion

29,300 SF Lease Renewal and Expansion

7,600 SF New Location

8,400 SF Lease Renewal

33,900 SF Relocation

10,200 SF Lease Renewal65,500 SF Lease Renewal and Expansion

30,100 SF Lease Renewal and Expansion

82,500 SF Lease Renewal65,280 SF Lease Renewal 13,000 SF Relocation

www.hughesmarino.com(619) 238-2111

55,600 SF Relocation

Leaders in Life Science Tenant Representation

Your Name: Jennifer ArthurJob title: VP, Finance

Favorite movie: The Great Race. Natalie Wood’s outfits were amazing, and Jack Lemon as Professor Fate was a riot! My favorite line in the movie is, ”Hit the button, Max”! Did I mention I have a son named Max? Enough said. Favorite book: The Phantom Tollbooth by Norton Juster. I loved that book as a kid and loved reading it to my four sons.

Favorite quote: “The lazy man always does twice the work.” Spanish proverb. But I know it from my father, Alex Gehr, saying it to my brother and I growing up. Now I say it to my kids.Favorite TV show: The Good Wife and ParenthoodFavorite restaurant or meal: My cousin Olga’s Colombian Empanadas with ajíFavorite city: EncinitasFavorite actor/actress: Robert Downey Jr. / Julianna MarguliesFavorite thing to do on the weekends: Along with my husband, watch and or play sports with our sonsWhat CD can we find in your car: I don’t play CD’s in the car anymore, but my favorite Pandora stations are Thievery Corporation, Duran Duran and George MichaelFavorite hobby: Running and golfingFavorite website: Amazon.com

Favorite spot in Southern California: Torrey Pines State ParkFirst job: Working at a dry cleaners. It was here that I learned the value of hard work and teamwork. Every Saturday morning I had to arrive an hour before the store opened. My first task of the day was to wax the rails by applying car wax to the assembly line rails while standing on a milk crate. I took great pride in knowing that my efforts contributed to the overall efficiency of the dry cleaners by making the hangers fly down the assembly line. Favorite part of your job: I love the culture and energy you find working for a start-up. The people are passionate and the science innovative. At COI Pharmaceuticals, I have the unique opportunity of being a part of forming and supporting several start-ups a year.If you could have another career, what would it be: Golf ProfessionalWhy did you start working in your industry: I wanted to be able to combine my love for finance with science.

www.coipharma.com

Innovative virtual product development approachMultidisciplinary strategy and plans from early stage to exit

Team of industry seasoned experts excel in delivering solutions for risk controlIntegration of technical and commercial considerations to maximize product value

Atheln is a Contract Development Organization delivering solutions to biopharma companies

www.athelnbiomed.com

Atheln-BioCom-Ad-Feb2015-final.indd 1 2/9/15 2:47 PM


Name: Tamera Weisser, Ph.D., J.D.Job title: Co-leader, Global Patent Prosecution Group & Partner

Favorite movie: Some Like It Hot by Billy Wilder Favorite books: To Kill a Mockingbird by Harper Lee Favorite quote: “Be the change that you wish to see in the world.” - Mahatma Ghandi Favorite TV show: House of Cards, Scandal, The Good Wife

Favorite restaurant or meal: Mama Mia’s in Milwaukee, WIFavorite city: Paris, FranceFavorite actor/actress: Cary Grant / Katherine HepburnFavorite thing to do on the weekends: Spend time with my husband and son.What CD can we find in your car: Joe Dirt Car by the BoDeansFavorite hobby: Cooking and gardeningFavorite website: Facebook and LinkedInFavorite spot in Southern California: My homeFirst job: Vendette selling popcorn at a movie theaterFavorite part of your job: Interacting with our clients and digging into the science behind their inventions to help provide a strategic business plan to company management.If you could have another career, what would it be: Something in the film industry.Why did you start working in your industry: I was a research scientist for almost 10 years in both academic and industry settings, which gave me an appreciation for the business side of science. I was able to parlay that experience into my legal career as an IP attorney representing primarily biotech and pharmaceutical company clients.

Name: Emad FareedJob title: Audit Partner - KPMG’s Life Science Practice

Favorite movie: The Godfather, Something about MaryFavorite books: The Alchemist, The Catcher in the RyeFavorite quote: “All that we are is the result of all that we have thought.” - Buddha Favorite TV show: Deadliest CatchFavorite restaurant or meal: Italian

Favorite city: New York (it’s where I grew up).Favorite actor/actress: Leonardo DiCaprio, Al PacinoFavorite thing to do on the weekends: Go swimming with my kids, anything outdoorsWhat CD can we find in your car: I don’t have CD’s but have a wide music taste that ranges from current top hits to hip hop. Anything but country.Favorite hobby: Fishing, playing any sportFavorite website: www.nytimes.com, www.espn.com Favorite spot in Southern California: Almost any beach, the beaches are beautiful here!First job: Tennis instructor for kids 3 to 15 – it was a great experience! I also was a golf caddy.Favorite part of your job: My life science clients deliver an important service to society. I enjoy helping my clients succeed through difficult issues so they can be most effective.If you could have another career, what would it be: Golf caddy for the PGA tour.Why did you start working in your industry: What drew me to public accounting and KPMG is the great sense of camaraderie and purpose behind the work performed. I really enjoy working with clients in the life sciences industry that are in different stages of their life cycle (from start-up, pre-revenue companies to commercially successful public companies).

www.jonesday.com www.kpmg.com


BIOCOM SPOTLIGHTName: Shaye ExnerJob title: Senior Director of Corporate Sponsorship

Favorite movie: RudyFavorite books: Who has time to read with 2 kids! The last book I read was called “Toddlers are !@#$holes” I enjoyed it immensely Favorite TV show: Childhood: Family Ties College: Felicity (still love it actually) My 20’s: Um SATC obvi Recent: Mad Men, Game of Thrones, Breaking Bad & Friday Night Lights

(Coach Taylor I love you!) Oh and the Vampire Diaries but I will never admit that in public. Oops. Favorite restaurant or meal: Best meal I have had in the last 12 months was at AVEC in Chicago. Amazing chorizo stuff dates!Favorite city: New York City or Chicago, I go where the food is.Favorite actor/actress: this changes all the time, but currently I like Oscar Isaac and Rosemarie DeWitt

Favorite thing to do on the weekends: Take my kids to the zoo or the park. Watching them play together (nicely) make me the happiest. That and drinking lots of wine.What CD can we find in your car: Do people still have CD’s in their car? Favorite hobby: Listening to Podcasts. Obsessed right now. Check out “The Moment with Brian Koppleman” or “Here’s the Thing” and obviously “This American Life”Favorite website: FacebookFavorite spot in Southern California: DisneylandFirst job: Concession Stand at the local movie theaterFavorite part of your job: Closing a dealIf you could have another career, what would it be: Psychologist


BOARD OF DIRECTORS

COMMITTEE LEADERSHIP

BOARD OFFICERS AND EXECUTIVE COMMITTEE:CHAIR: Theodore Schroeder*VICE CHAIR: Carin Canale-Theakston, Canale Communications*CHAIR ELECT: Daniel Burgess*VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper*VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young*VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield*CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)* PRESIDENT & CEO: Joe Panetta, Biocom*Vincent Anido, Ph.D., Aerie PharmaceuticalsSteven Bartz, Ph.D., Merck & CompanyScott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & PopeoMichael Boyd, AbbVieMichael Brown, Stradling Yocca Carlson & RauthTerrance J. BruggemanJohn M. DunnStephen Ferruolo, J.D., Ph.D., USD School of Law*M. Wainwright Fishburn, Jr., Cooley LLP*Don Fitzgerald, GenentechJack FlorioGregory Fond, Sanofi Global R&DGregory Frost, Intrexon Corp.Carol GallagherJeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & RosatiJason Hannon, NuVasiveRichard Heyman, Ph.D.Elliot Hirshman, Ph.D., San Diego State UniversityMatthew Hudes, Deloitte LLPGuy J. Iannuzzi, MentusGerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research FoundationDavid Kabakoff, Ph.D., Sofinnova VenturesSteve Kaldor, Ph.D., QuanticelKatherine Kantardjieff, Ph.D., California State University San MarcosPaul Laikind, Ph.D., ViaCyteJacob Levin, Ph.D., UC IrvineJames Levine, Sapphire Energy*Jack Lief, Arena Pharmaceuticals, Inc.*John Lister, DexcomDamien McDevitt, Ph.D., GlaxoSmithKline

Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*William Molloie, PwCTracy Murphy, Biomed Realty TrustPaul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.*Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research InstituteBrian O’CallaghanKenneth Polin, Jones DayTrindl Reeves, Barney & Barney LLC*Gregory Reyes, M.D., Ph.D., CelgeneDan Ryan, Alexandria Real Estate EquitiesCamille Saltman, Malama Composites, Inc.James Schaeffer, Ph.D., Calibr*Christophe Schilling, Ph.D., Genomatica, Inc.*Timothy Scott, Pharmatek*Bhasker Shetty, Ph.D., Pfizer La JollaLarry Stambaugh, Kalos Therapeutics*Mark Stevenson, Thermo Fisher Scientific*Tsuneo Takahashi, NF CorporationScott N. Wolfe, Latham & Watkins

LIFE DIRECTOR:Kennon W. Baldwin, Ferguson Pape Baldwin Architects*David Hale, Hale BioPharma Ventures*Tina Nova, Ph.D., Ilumina

Biocom Board Members-Ex-Officio:Sandra Brown, Ph.D., UCSDMark Cafferty, San Diego Regional Economic Development CorporationConstance Carroll, Ph.D., San Diego Community College DistrictScott Lippman, MD, Moores Cancer Center, UCSDGreg McKee, CONNECTPeter Preuss, The Preuss FoundationJerry Sanders, San Diego Regional Chamber of CommerceDavid Webb, Ph.D., Scripps Research Institute

*Executive Committee Member

BIG DATAGeorge Bonaros, Biocom

BIocom InsTITuTe BoArD commITTee*Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.

cApITAl DevelopmenT commITTee*Carin Canale-Theakston, Canale Communications

David Kabakoff, Ph.D., Sofinnova Ventures

cro commITTee

Timothy Scott, Pharmatek

envIronmenTAl, HeAlTH AnD sAfeTy commITTeeCliff HannaDan Shiel, Pfizer La Jolla

fAcIlITIes commITTeeAndy Darragh, Ferguson Pape Baldwin Architects

Brent D. Jacobs, Cushman & Wakefield

fDA commITTeeMagda Marquet, Ph.D.,Althea (A member of the Ajinomoto Group)Michele Yelmene, Pharmalink Consulting

InTellecTuAl properTy AnD pATenT lAw commITTeeDaniel Hart, Knobbe Martens Olson & Bear LLPMichael Mueller, Conatus Pharmaceuticals

InTernATIonAl commITTee

Kenneth Polin, Jones Day

leGIslATIve commITTeeRichard LedfordApril Grant, Sunovion Pharmaceuticals

meDIcAl DevIce commITTeeMike Oliver, Spectra ScienceJoleen Schultz, Rady School of Management, UCSD

DIGITAl HeAlTH commITTee

Kira Jenkins, Biocom

puBlIc polIcy oversIGHT commITTee*Larry Stambaugh, Kalos Therapeutics

Paul Laikind, ViaCyte

purcHAsInG BoArD commITTee*Jack Lief, Arena Pharmaceuticals, Inc.

scHolArsHIp commITTeeBente Hansen, BenteHansen and Associates

veTerAns commITTeeJosh Vosovic

*Board Level Committees


BIOTECHNOLOGYAbcoreAbgentAbide TherapeuticsAbilita Bio*Abwiz BioACADIA PharmaceuticalsActivX BiosciencesAdvanced BioMatrixAdvanced Targeting SystemsAerie PharmaceuticalsAfraxisAgena BioscienceAjinomoto Pharmaceuticals*AM ChemicalsAMBRXAmbryx BiotechnologyAmgenAmicrobeAmplyx PharmaceuticalsAnaptysBioAndroScienceAnsun BiopharmaApricus BiosciencesArcturus TherapeuticsArdea BiosciencesArrayomicsArytha Biosciences*Astellas PharmaaTyr PharmaAuspex PharmaceuticalsAvantgenAvelasAvidity NanoMedicinesAviva BiosciencesBachem AmericasBASFBioLegendBiomatricaBiomyxBioNano GenomicsBionomicsBio OptionsBioSpyder TechnologiesBioWaBoehringer-IngelheimCurtana PharmaceuticalsCalciMedicaCannaVest Corporation

Cell ApplicationsCelladonCellana Center for Aquaculture TechnologiesChubu Technology Licensing OfficeCibusCidara TherapeuticsCoda TherapeuticsConju-ProbeContract BioticsCosmederm Bioscience*Crinetics PharmaceuticalsCypher GenomicsDart NeuroscienceDefiniensDiomics CorporationDNA Link USA*DNAtrixDSM Food SpecialtiesE&B TechnologiesEdico Genome*eFFECTOR TherapeuticsElcelyx TherapeuticsElectronic BioScienceseMoleculesEpeius BiotechnologiesEquitech BioEton BioscienceFabrusFate TherapeuticsForge Therapeutics*FormexGenelux CorporationGenentechGenlantisGenoa PharmaceuticalsGenomaticaGenovo CorporationGenSignia Life SciencesGigaGenGlaxoSmithKlineGlobal Medical & Research

TechnologiesGuangdong Consun Pharmaceutical

CompanyGWR InstrumentsHalozyme TherapeuticsHistogenHuman LongevityHuya Bioscience International

IDEXX BioResearchIlluminaImprimis PharmaceuticalsInception SciencesIndi Molecular*InhibrxInnoPepInnovative Cell TechnologiesInnovus Pharmaceuticals*Inovio PharmaceuticalsIntegrated DNA TechnologiesIntercept PharmaceuticalsInternational Stem CellIntrepid TherapeuticsIntrexon CorporationIntrinsic LifeSciencesInvetechInvivoGenIRBCo.ISIS PharmaceuticalsJ-Oil MillsJSR MicroKalos TherapeuticsKalyra PharmaceuticalsKoltan PharmaceuticalsKura OncologyKyowa Hakko Kirin CaliforniaLa Jolla BiologicsLa Jolla Pharmaceutical CompanyLigand PharmaceuticalsLpathLumena PharmaceuticalsMabVax TherapeuticsMalama CompositesMast TherapeuticsMDRejuvena*MEI PharmaMeiji Seika Pharma*Meritage PharmaMirati TherapeuticsMonsantoMultiVirNautilus EnvironmentalNeotheticsNeuroGenetic PharmaceuticalsNF Techno CommerceNitto Denko TechnicalNovartis PharmaceuticalsNovo NordiskNucelis

OBI Pharma USA*Ocera TherapeuticsOhr PharmaceuticalsOptimum TherapeuticsOrexigen TherapeuticsOrPro TherapeuticsOtonomyPacira PharmaceuticalsPanmira PharmaceuticalsPatara PharmaPathway GenomicsPersImmunePfenexPharmAkeaPolaris GroupPolynomaPolyPeptide GroupPoseida Therapeutics*Predictive BiologyPrimaPharmPrimeGen BiotechPrimordial GeneticsPrognosys BiosciencesProSciQED BioscienceQingdao Ming Yaotang Medical

TechnologyQingdao Newsummit New Drug Public

Service R&D PlatformQuanticel PharmaceuticalsReceptosRegulus TherapeuticsREKA HealthRempex PharmaceuticalsRenova TherapeuticsRibomed BiotechnologiesRidgeline EngineeringRoche Applied ScienceRohto PharmaceuticalRQX PharmaceuticalsRuiYiSapphire EnergySamumedSamsara SciencesSanofiSciencescapeScripps LaboratoriesSenior Scientific*Senju USASenomyx

SentéSeragon PharmaceuticalsSGBSilicon BiosystemsSirenas Marine DiscoverySolstice BiologicsSomaLogicSophiris BioSorrento TherapeuticsSOVA PharmaceuticalsSparsha Pharma USA*Stemedica Cell TechnologiesStemImmune*Sunovion PharmaceuticalsSynteractHCRSynthetic GenomicsTakeda Pharmaceuticals U.S.A.Tanabe Research LaboratoriesTEGA TherapeuticsTenova PharmaceuticalsThesan PharmaceuticalsTocagenTonbo BiosciencesTP TherapeuticsTracon PharmaceuticalsTragara PharmaceuticalsTriphase AcceleratorTriton Health & Nutrition*UCBUS Specialty LabsVantari GeneticsVaxiion TherapeuticsVerdezyneVertex PharmaceuticalsVet-StemViaCyteVicalViking TherapeuticsVisionary PharmaceuticalsVital TherapiesWellspring BiosciencesWildcat Discovery TechnologiesWorld Fusion USXencorXycrobe TherapeuticsZogenix

PREMIUMAbbVieAirgasAldevron*Alexandria Real Estate EquitiesAltheaArena PharmaceuticalsBayer HealthcareBiogen*Biomed Realty TrustBiospace

BP BiofuelsCalifornia Manufacturing

Technology ConsultingCanale CommunicationsCelgeneCity National BankCOI PharmaceuticalsConatus PharmaceuticalsCooley LLPDeloitteDLA Piper

Eli LillyErnst & YoungEvaluate Pharma*Ferring Research InstituteFisher ScientificFoley & LardnerGE Healthcare Life SciencesGenoptixHologicJ-LabsJones Day

KPBSKPMG*Latham & WatkinsMallinckrodt PlcMentusMerck Research Laboratories of

San DiegoMintz, Levin, Cohn, Ferris,

Glovsky and PopeoNuVasiveOffice Depot

PfizerPraxairPrometheus LaboratoriesPwCThermo Fisher ScientificUnisource SolutionsVWR InternationalWilson Sonsini Goodrich &

Rosati

BIOCOM MEMBERSHIP



NON-PROF I TAmerican Cancer Society, Border

Sierra RegionBattelleCA Institute for Regenerative MedicineCalibrCalifornia Baptist University, College of

EngineeringCalifornia Medical Innovations

InstituteCalifornia State University, San MarcosCase Western Reserve, School of

Engineering*City Of MuriettaCONNECTConsulate Of CanadaCSU,CSUPERB ProgramHuman BioMolecular Research

InstituteInstitute of Engineering in MedicineISM San DiegoJ. Craig Venter InstituteKaiser PermanenteLa Jolla Bioengineering InstituteLa Jolla Institute for Allergy &

ImmunologyLawrence Family Jewish Community

CenterLos Angeles Biomedical Research

InstituteMedicon Valley AllianceMiraCosta College Biotech ProgramMt. San Jacinto CollegePhRMAPoint Loma Nazarene UniversityRady School of Management, UCSDSalk Institute For Biological Studies

San Diego Biomedical Research Institute

San Diego Blood BankSan Diego Clinical and Translational

Research Institute, UCSDSan Diego Community College DistrictSan Diego Employers AssociationSan Diego Regional Chamber of

CommerceSan Diego Regional Economic

Development Corp.San Diego Supercomputer Center

(UCSD)San Diego Workforce PartnershipSanford-Burnham Medical Research

InstituteScottish Development InternationalScripps HealthScripps Research Institute

Swedish American Chamber Of Commerce San Diego

The BioIndustry AssociationThe Lowy Medical Research Institute

(LMRI)Torrey Pines Institute for Molecular

StudiesUC San Diego ExtensionUCI’s Office of ResearchUCSD, Department of BioengineeringUCSD, Health Systems- Center for

Occupational & Environmental Medicine

UCSD, Office of AdvancementUCSD School of MedicineUCSD, Technology Transfer OfficeUK Trade & InvestmentUniversity of San Diego

INDIV IDUALAntoinette AzevedoBernard KingCarol GallagherDonna JansonElliot ParksGary FriedmanJohn DunnJohn KavanaghJulie AmesPeter PreussRichard LedfordStan Kim*

MEDIC AL DEV ICE & D IAGNOST ICAcon LaboratoriesAethlon MedicalAlphatec SpineAltheaDxAmydis Diagnostics*Applied ProteomicsAstute MedicalAxonics Modulation TechnologiesBanyan BiomarkersBeneChillBioceptBioDxBiological DynamicsBiomericabioTheranosticsBreathe TechnologiesBruin BiometricsCell Idx

CeloNova BioSciencesCelulaCliniqa CorporationClinMetCombiMatrix*CompellonCritical DiagnosticsCure CareCTK BiotechCVAC SystemsCytori TherapeuticsDermTech InternationalDexComDiagnostic Consulting NetworkDorsa Vi USAEllipse TechnologiesEmerge DiagnosticsEndologixEnigma DiagnosticsEntra Health SystemsEpic Sciences

Epitope DiagnosticsFallbrook EngineeringFemCapFortimedix USAFreedom MeditechGenomeDx Biosciences*GenWay BiotechGIMDx*Glaukos CorporationGlysensHitachi Chemical Research CenterHygeia MedicalIchor Medical SystemsIgnytaImpediMedImThera MedicalInari MedicalInceptus MedicalINOVA DiagnosticsInterpretaInterventional Spine

InVision Biomedical GroupInvivoscribe TechnologiesIonian TechnologiesIvantisIvera MedicalKFx MedicalMARDX DiagnosticsMedipacsMicell TechnologiesMillennium HealthNano Imaging ServicesNanomedical DiagnosticsNuFACEOmniomeOncoSec Medical OrganovoParallel 6Pediatric BiosciencePrometheus LaboratoriesQualigenQuidel

Quinn MedicalReShape MedicalREVA MedicalReVision OpticsRoka BioscienceSequenomSequent MedicalShireSienna LabsSirigenSonendoSpectraScienceSpinal Elements*Suneva MedicalTandem DiabetesTargesonTherOxTristan TechnologiesTrovageneUptake MedicalYulex

BIOCOM MEMBERSHIP

CRO/CMO3DT Holdings*AbbiotecABL*Absorption SystemsAccelagenAccugent LaboratoriesAcurianAdvantar LaboratoriesAgility ClinicalAlliance Protein LaboratoriesA&M Biomedical*Ambit BiosciencesAmerican Peptide CompanyAnaBiosAnimantisAnnova ChemARIANNE

AthelnBeaufort CROBehavioral PharmaBend ResearchBioAgilytix LabsBioAtlaBioserv CorporationBTS ResearchCalChem SynthesisCassiaCato ResearchCharles River LaboratoriesChemDivCombi-BlocksConcortis Biosystems Crown Bioscience San Diego*CytelligenDavos ChemicalDD Studio

Drug Delivery ExpertsEpistemeStudySiteExon BioSystemsExpertise EngineeringExplora BioLabsGENEWIZGRAM LaboratoriesHamari Chemical San Diego Research

CenterHD BiosciencesHuntingdon Life SciencesIMS HealthIntegrium Clinical ResearchInterplex SunbeltinVentive Health ClinicalIriSysiXCells Biotechnologies USA*JadeBio

LCMS SolutionsMediconomicsMicroConstantsMolecular ResponseMPI ResearchMy Chem LLCNeuroserviceNeuro-SysOuterspace Design Group*PacificGMPPharPoint ResearchPharmaDirections*Pharmatek LaboratoriesProfil Institute For Clinical ResearchPSI CROPuracypQuadrants ScientificReveal BiosciencesRho

Robarts Clinical TrialsRoowinSAFC PharmaSherpa Clinical PackagingSpaulding Clinical ResearchStarfish MedicalTherapeutics, Inc.Tioga ResearchToxikonTriligent InternationalUltimate LabsVerum.usVIRAPURWax-It Histology ServicesWuXi AppTecZensun USAZyagen



KEY PROVIDERBarney & BarneyCushman & WakefieldOracle Health SciencesQualcommSan Diego Gas & Electric

PROVIDER2ConnectAccelrysADVIAER TravelAIS Data CentersAlexander’s Mobility ServicesAlliant Insurance*AMN HealthcareAssay DepotBank of AmericaBeckloff AssociatesBench InternationalBente Hansen & AssociatesBerkshire Hathaway Home Services Bionest PartnersBioSurplusBiotech PrimerBiotech VendingBioTixBlue Sky BroadcastBootstrap Incubation

Brizzey*Caliber Associates California Commercial SecurityCambridge Research BiochemicalsCanteen Vending ServicesCBRECentral Pharma Contract Packaging*China Business PartnersChubb Group of Insurance CompaniesClinigen HealthcareCoastal Payroll Services*Controlled Contamination ServicesCorningCovisint CorporationCox BusinessCymerDomain AssociatesEBD GroupElsevierEntereyEquipNetEuretosExp U.S. ServicesFerguson Pape Baldwin ArchitectsFisher & PhillipsForward VenturesFragomen, Del Rey, Bernsen & LoewyFrench BiobeachFrequentzGable PRGensler

Grande ColonialGreen Charge Networks*Gunderson Dettmer*Hartl Team- Private Banking &

Investment Group- Merrill LynchHaworthHCP Life Science EstatesH.G. Fenton CompanyHyatt Regency La Jolla at AventineIBM Life SciencesInnovative Lease ServicesIntersection*J.T. MacMillan PhotographyJackson & Blanc HVAC ContractorsJones Lang LaSalleKilroy RealtyKnobbe, Martens, Olson & BearLeadership EdgeLegacy Partners CommercialLife Science IT*Lonza AGManaged Laboratory ServicesManaged SolutionMayer Hoffman McCannMcKenna Long & AldridgeMedidata SolutionsMedline IndustriesMehlman BarnesMercury FundMorgan, Lewis & BockiusMorrison & Foerster

Newhoff Healthcare Communications*Occupational ServicesOrion International Patent OfficeOxford FinancePharmalink ConsultingPharmour*PR NewswirePrevost ConstructionProcopio, Cory, Hargreaves & SavitchProject Management AdvisorsRetirement DNASan Diego World Trade CenterSartoriusSecureDocsScient Federal Credit Union Sharp Business SystemsSheppard Mullin Richter & HamptonShred San DiegoSignature AnalyticsSilicon Valley BankSofinnova VenturesSonceboz CorporationSpeid & Associates* Square 1 BankS Squared Executive SearchStradling Yocca Carlson & RauthSavills StudleySughrue MionSurplus Solutions*Technical Safety ServicesThe Business Cleaning Company

The HealthEd GroupThe Sandler GroupThomas, Mcnerney & PartnersTime Warner CableUnanet*UnifirstUnited Parcel Service (UPS)Vault Bioventures*VDP DirectVeoliaWCCT Global

Beijing | Brussels | Century City | Chicago | Del Mar | London | Los Angeles | New YorkOrange County | Palo Alto | San Diego | San Francisco | Seoul | Shanghai | Washington, D.C.

www.sheppardmullin.com

Legal Counsel to the Life Sciences Industry• Formation and Organization

• Intellectual Property

• Clinical Trials

• FDA Regulatory

• Healthcare Regulatory

• Labor and Employment

• Real Estate

• Litigation

Contact:Don Pelto, [email protected] | 202.747.1911

Lorna Tanner, [email protected] | 650.815.2658

For more information and to register:(858) 534-9353 | [email protected]/lifesciences

August 12-14, 2015 | 8:00 a.m. – 5:00 p.m. UC San Diego Campus, La Jolla, CA

3-DAY EVENTMicrobial FermentationWorkshopThis 3-day workshop, developed in partnership between UC San Diego’s Center for Continuing Education in Biosciences (CCE|BIO) and UC San Diego Extension, is designed to provide a deep dive into bioreactor operations for microbial fermentations and equip you with the knowledge and practical skills needed to optimize your processes. Designed for professionals with fundamental experience in fermentation, this program will facilitate the exploration of bioprocess simulation, economics and modern techniques used in applying process analytical technology in manufacturing.

• Apply biological principles to problems involving microbial growth systems

• Comprehend modern techniques used in applying process analytical technology in manufacturing

• Examine bioreactor operations in microbial cell systems and the scale-up of bioreactors

Fermentor Demos by

DCI-Biolafitte

SPEAKERS:

JAMES GOLDEN, PH.D., Professor, UC San Diego

MICHAEL FINO, M.ENG., Faculty, MiraCosta College

JEFF LIEVENSE, PH.D., Senior Engineering Fellow, Genomatica

JON HANSEN, PH.D., Sr. Technical Director, DSM

TIM DODGE, PH.D., Sr. Staff Scientist, Dupont

MICHAEL JAPS, Process Development Engineer, Genomatica

10996 Torreyana Rd, Suite 200San Diego, CA 92121-3021

www.Biocom.org

Please send a change of address or subscription request to Sonali Vittachi at [email protected].

Biocom: Bringing Your Concerns to to You LifeLines · 2020. 2. 20. · CUBIST 45,000 SF / Sublease...

Documents

Transcript of Biocom: Bringing Your Concerns to to You LifeLines · 2020. 2. 20. · CUBIST 45,000 SF / Sublease...